QLOSI Drug Patent Profile
✉ Email this page to a colleague
When do Qlosi patents expire, and what generic alternatives are available?
Qlosi is a drug marketed by Orasis Pharms and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-three patent family members in fourteen countries.
The generic ingredient in QLOSI is pilocarpine hydrochloride. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Qlosi
A generic version of QLOSI was approved as pilocarpine hydrochloride by PADAGIS US on November 16th, 2004.
Summary for QLOSI
| International Patents: | 23 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | QLOSI at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for QLOSI
US Patents and Regulatory Information for QLOSI
QLOSI is protected by three US patents and one FDA Regulatory Exclusivity.
Patents protecting QLOSI
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PRESBYOPIA
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PRESBYOPIA
Ophthalmic pharmaceutical compositions and uses relating thereto
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PRESBYOPIA
FDA Regulatory Exclusivity protecting QLOSI
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Orasis Pharms | QLOSI | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 217836-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QLOSI
See the table below for patents covering QLOSI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2023226732 | Ophthalmic pharmaceutical compositions and uses relating thereto | ⤷ Try a Trial |
| Canada | 3031370 | COMPOSITIONS PHARMACEUTIQUES OPHTALMIQUES ET UTILISATIONS ASSOCIEES (OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO) | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2018033792 | ⤷ Try a Trial | |
| South Korea | 102588499 | ⤷ Try a Trial | |
| Poland | 3500255 | ⤷ Try a Trial | |
| European Patent Office | 3500255 | COMPOSITIONS PHARMACEUTIQUES OPHTALMIQUES ET UTILISATIONS ASSOCIÉES (OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO) | ⤷ Try a Trial |
| Russian Federation | 2019107585 | ОФТАЛЬМОЛОГИЧЕСКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
